Inspire Medical Systems (NYSE:INSP) Stock Gets Price Target Cut from Barclays

Inspire Medical Systems (NYSE:INSP) had its price target reduced by analysts at Barclays from $65.00 to $62.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “underweight” rating on the stock. Barclays‘s price objective suggests a potential downside of 0.87% from the company’s previous close.

A number of other brokerages also recently issued reports on INSP. Wells Fargo & Company set a $69.00 price target on shares of Inspire Medical Systems in a report on Tuesday. Robert W. Baird upped their price objective on Inspire Medical Systems from $73.00 to $77.00 and gave the company a “neutral” rating in a report on Tuesday. Mizuho set a $75.00 price objective on Inspire Medical Systems in a report on Tuesday, October 13th. Evercore set a $54.00 target price on Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Piper Sandler lifted their target price on Inspire Medical Systems from $60.00 to $70.00 and gave the company a “neutral” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus price target of $70.94.

Inspire Medical Systems Stock Performance

Shares of INSP stock traded down $4.66 on Tuesday, hitting $62.55. 94,749 shares of the stock traded hands, compared to its average volume of 1,040,750. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The firm’s 50-day moving average price is $68.69 and its two-hundred day moving average price is $58.82. The stock has a market capitalization of $1.81 billion, a PE ratio of 13.53, a PEG ratio of 5.37 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $206.69 million during the quarter, compared to analysts’ expectations of $204.31 million. During the same period last year, the business earned $0.38 earnings per share. Inspire Medical Systems’s revenue was down 7.9% compared to the same quarter last year. On average, equities research analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Inspire Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pinnacle Wealth Planning Services Inc. lifted its stake in Inspire Medical Systems by 19.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock worth $81,000 after acquiring an additional 194 shares during the last quarter. Apollon Wealth Management LLC increased its position in shares of Inspire Medical Systems by 5.6% in the 1st quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock valued at $206,000 after purchasing an additional 212 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Inspire Medical Systems by 25.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,526 shares of the company’s stock valued at $106,000 after purchasing an additional 305 shares during the last quarter. Yousif Capital Management LLC increased its position in shares of Inspire Medical Systems by 5.7% in the 3rd quarter. Yousif Capital Management LLC now owns 7,552 shares of the company’s stock valued at $524,000 after purchasing an additional 405 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Inspire Medical Systems by 68.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock valued at $83,000 after purchasing an additional 488 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter adjusted EPS of $0.14, ahead of the $0.09 consensus estimate, while revenue of approximately $206.7 million exceeded expectations of $204.3 million. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company’s fiscal 2026 guidance has a midpoint of $1.30 for EPS and $855 million for revenue, modestly above consensus estimates of $1.25 and $853.6 million, respectively. This suggests execution is holding up despite reimbursement-related pressure.
• Positive Sentiment: Robert W. Baird raised its price target from $73 to $77, and Piper Sandler lifted its target from $60 to $70. Both firms retained neutral ratings, indicating improved valuation expectations but limited conviction in a stronger near-term recovery.
• Neutral Sentiment: Management said reimbursement and coding conditions are stabilizing and projected low-single-digit revenue growth for 2027. Stabilization reduces a major business risk, but the expected growth rate remains modest.
• Negative Sentiment: Third-quarter revenue declined 7.9% from the prior year, and EPS fell from $0.38 to $0.14. The results beat reduced expectations but still reflect weaker underlying growth and profitability.
• Negative Sentiment: The neutral analyst ratings and low-single-digit 2027 growth forecast may limit enthusiasm, particularly after Inspire’s shares have already rebounded substantially from their 52-week low.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.